Skip to Main Content

Skip Nav Destination

Issues

Select Year

Issue

Volume 18, Issue 16

15 August 2012

Cover Image

Cover Image

Fusions of the ROS1 kinase occur in about 1.5% of NSCLC cases. In a subset of these tumors, ROS1 fusion protein and mutant EGFR protein were found to be localized in the same area on serial sections, suggesting that coexpression of the two important therapeutic RTK targets can occur in NSCLC. Immunohistochemical staining of total EGFR protein is shown in a SLC34A2-ROS1 fusion positive NSCLC tumor. For details, see the article by Rimkunas and colleagues on page 4449 of this issue.
Table of Contents

ISSN 1078-0432

EISSN 1557-3265